Risk-based quality management (RBQM) is now widely recognised as crucial to improving data quality and clinical trial efficiency. Regulatory backing and increasing complexity are driving adoption and the RBQM market is expected to maintain a CAGR of 12% through 2033, reaching approximately $7 billion. The percentage of clinical trials implementing RBQM elements by 2027 is expected to increase to 82% in planning and design, 81% in execution and monitoring and 79% in documentation and resolution.